MX355181B - Anticuerpos humanos contra el factor tisular. - Google Patents
Anticuerpos humanos contra el factor tisular.Info
- Publication number
- MX355181B MX355181B MX2016005494A MX2016005494A MX355181B MX 355181 B MX355181 B MX 355181B MX 2016005494 A MX2016005494 A MX 2016005494A MX 2016005494 A MX2016005494 A MX 2016005494A MX 355181 B MX355181 B MX 355181B
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies against
- human
- tissue factor
- human antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a un anticuerpo humano, o fragmento de unión del mismo, el cual se une a factor tisular humano, caracterizado porque el anticuerpo comprende: c) una región VH que comprende las secuencias de la CDR1, 2 y 3 de la SEQ ID NO: 34, 35 y 36 y una región VL que comprende las secuencias CDR1, 2 y 3 de la SEQ ID NO: 90, 92 y 92, o d) una variante del anticuerpo, en donde la variante preferiblemente tiene como máximo 1, 2 ó 3 modificaciones de aminoácidos, de manera más preferible sustituciones de aminoácidos tales como sustituciones conservadoras de aminoácidos en las secuencias.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20133508P | 2008-12-09 | 2008-12-09 | |
DKPA200801744 | 2008-12-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX355181B true MX355181B (es) | 2018-04-09 |
Family
ID=59050110
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011005669A MX338754B (es) | 2008-12-09 | 2009-12-09 | Anticuerpos humanos contra el factor tisular. |
MX2016005494A MX355181B (es) | 2008-12-09 | 2011-05-27 | Anticuerpos humanos contra el factor tisular. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011005669A MX338754B (es) | 2008-12-09 | 2009-12-09 | Anticuerpos humanos contra el factor tisular. |
Country Status (21)
Country | Link |
---|---|
US (6) | US9150658B2 (es) |
EP (3) | EP3159358B1 (es) |
JP (6) | JP5860285B2 (es) |
KR (2) | KR101736447B1 (es) |
CN (2) | CN102317319B (es) |
AU (1) | AU2009324412B2 (es) |
BR (1) | BRPI0922350B8 (es) |
CA (2) | CA2746101C (es) |
DK (1) | DK2376537T3 (es) |
EA (1) | EA201100923A1 (es) |
ES (1) | ES2604635T3 (es) |
IL (1) | IL212856A (es) |
MX (2) | MX338754B (es) |
NZ (1) | NZ786274A (es) |
PL (1) | PL2376537T3 (es) |
PT (1) | PT2376537T (es) |
SG (1) | SG10201500140VA (es) |
SI (1) | SI2376537T1 (es) |
UA (1) | UA109633C2 (es) |
WO (1) | WO2010066803A2 (es) |
ZA (1) | ZA201103723B (es) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003295471B2 (en) * | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
US9085625B2 (en) * | 2008-12-03 | 2015-07-21 | Genmab A/S | Antibody variants having modifications in the constant region |
UA109633C2 (uk) | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
AU2011257121A1 (en) | 2010-05-27 | 2013-01-10 | Genmab A/S | Monoclonal antibodies against HER2 |
JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
AR084053A1 (es) * | 2010-11-30 | 2013-04-17 | Chugai Pharmaceutical Co Ltd | Agente terapeutico que induce citotoxicidad |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
CN103796677B (zh) * | 2011-04-20 | 2019-08-16 | 健玛保 | 针对her2和cd3的双特异性抗体 |
CN103796678B (zh) * | 2011-04-20 | 2018-02-27 | 健玛保 | 针对her2的双特异性抗体 |
UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
US9555109B2 (en) * | 2012-01-20 | 2017-01-31 | University Of Cincinnati | Method of inhibiting cell proliferation induced by alternatively spliced tissue factor by administering a monoclonal antibody |
US11180572B2 (en) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Dimeric protein with triple mutations |
EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
EP2943506B1 (en) | 2013-01-10 | 2024-03-13 | Genmab B.V. | Human igg1 fc region variants and uses thereof |
JP2017502983A (ja) * | 2013-10-02 | 2017-01-26 | スリ テクノロジーズ エルティーディー. | 不均一な腫瘍を処置するための患者特異的免疫療法 |
CN113521016A (zh) | 2013-11-21 | 2021-10-22 | 根马布股份公司 | 抗体-药物缀合物冻干制剂 |
WO2016077720A1 (en) * | 2014-11-14 | 2016-05-19 | Protein One, Llc | Binding agents and uses thereof |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL297418B2 (en) | 2015-02-18 | 2023-11-01 | Enlivex Therapeutics Rdo Ltd | Combined immunotherapy and cytokine control therapy for cancer treatment |
IL287500B2 (en) | 2015-04-21 | 2023-12-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic preparations from pooled apoptotic blood cells and their use |
WO2018036117A1 (zh) * | 2016-08-22 | 2018-03-01 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
WO2017028823A1 (zh) * | 2015-08-20 | 2017-02-23 | 复旦大学 | 靶向于组织因子的抗体、其制备方法和用途 |
SI3347054T1 (sl) | 2015-09-11 | 2021-08-31 | Genmab A/S | Režimi doziranja konjugatov zdravil proti TF protitelesu |
US11730761B2 (en) | 2016-02-18 | 2023-08-22 | Enlivex Therapeutics Rdo Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
CN106938051B (zh) | 2016-08-22 | 2019-10-11 | 复旦大学 | 靶向于组织因子的抗体-药物偶联物 |
US11021533B2 (en) | 2016-11-02 | 2021-06-01 | Vanderbilt University | Human Zika virus antibodies and methods of use therefor |
TW201922796A (zh) * | 2017-10-30 | 2019-06-16 | 國立研究開發法人國立癌症研究中心 | 可用於實體腫瘤治療之抗體及其抗體-藥物共軛物以及含其之抗癌劑 |
EP3703757A4 (en) * | 2017-11-02 | 2021-08-04 | Genmab A/S | ANTIBODY ANTI-TISSUE FACTOR-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER |
US20220153871A1 (en) | 2018-01-04 | 2022-05-19 | Iconic Therapeutics, Inc. | Anti-Tissue Factor Antibodies, Antibody-Drug Conjugates, and Related Methods |
TW202010755A (zh) | 2018-05-07 | 2020-03-16 | 丹麥商珍美寶股份有限公司 | 使用抗pd-1抗體與抗組織因子抗體-藥物共軛體之組合以治療癌症之方法 |
CN112368020A (zh) | 2018-05-07 | 2021-02-12 | 展马博联合股份有限公司 | 抗pd-1抗体和抗组织因子抗体-药物偶联物组合治疗癌症的方法 |
MX2021001058A (es) * | 2018-08-16 | 2021-04-12 | Genmab As | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de un cancer. |
TW202034958A (zh) | 2018-10-30 | 2020-10-01 | 丹麥商珍美寶股份有限公司 | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 |
CN109840471B (zh) * | 2018-12-14 | 2023-04-14 | 天津大学 | 一种基于改进Unet网络模型的可行道路分割方法 |
US20220056155A1 (en) * | 2018-12-21 | 2022-02-24 | Board Of Regents, The University Of Texas System | Phosphorylated dicer antibody and methods of use thereof |
SG11202108398YA (en) | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
KR102652906B1 (ko) | 2019-04-17 | 2024-04-01 | 노보 노르디스크 에이/에스 | 이중 특이적 항체 |
TW202131954A (zh) | 2019-11-07 | 2021-09-01 | 丹麥商珍美寶股份有限公司 | 利用鉑類劑與抗組織因子抗體-藥物共軛體之組合來治療癌症之方法 |
CA3155754A1 (en) | 2019-11-07 | 2021-05-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
IL297167A (en) | 2020-04-10 | 2022-12-01 | Seagen Inc | Charging variant connectors |
JP2023533937A (ja) | 2020-06-29 | 2023-08-07 | ジェンマブ エー/エス | 抗組織因子抗体-薬物コンジュゲートおよびがん治療におけるその使用 |
BR112023000455A2 (pt) * | 2020-07-10 | 2023-03-28 | Iconic Therapeutics Inc | Tratamento de doença inflamatória que usa anticorpos de fator antitecidual |
US11965024B2 (en) | 2020-09-11 | 2024-04-23 | Janssen Biotech, Inc. | Methods and compositions for modulating beta chain mediated immunity |
WO2022056197A1 (en) * | 2020-09-11 | 2022-03-17 | Janssen Biotech, Inc. | Immune targeting molecules and uses thereof |
TW202233248A (zh) | 2020-11-08 | 2022-09-01 | 美商西健公司 | 組合療法 |
KR20230171980A (ko) | 2021-04-20 | 2023-12-21 | 씨젠 인크. | 항체 의존성 세포 독성의 조절 |
CA3221398A1 (en) | 2021-05-28 | 2022-12-01 | Seagen Inc. | Anthracycline antibody conjugates |
WO2023137399A2 (en) * | 2022-01-12 | 2023-07-20 | Iconic Therapeutics Llc | Inflammatory disease treatment using anti-tissue factor antibodies |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
WO2023213960A1 (en) | 2022-05-06 | 2023-11-09 | Genmab A/S | Methods of treating cancer with anti-tissue factor antibody-drug conjugates |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077A (en) | 1849-01-30 | Improved hinged claw-wrench | ||
US835A (en) | 1838-07-12 | X i i i x | ||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
DE3380726D1 (en) | 1982-06-24 | 1989-11-23 | Japan Chem Res | Long-acting composition |
US4681581A (en) | 1983-12-05 | 1987-07-21 | Coates Fredrica V | Adjustable size diaper and folding method therefor |
US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
US4735210A (en) | 1985-07-05 | 1988-04-05 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US5101827A (en) | 1985-07-05 | 1992-04-07 | Immunomedics, Inc. | Lymphographic and organ imaging method and kit |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
US5437864A (en) | 1987-03-31 | 1995-08-01 | The Scripps Research Institute | Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor |
US5750172A (en) | 1987-06-23 | 1998-05-12 | Pharming B.V. | Transgenic non human mammal milk |
US5648471A (en) | 1987-12-03 | 1997-07-15 | Centocor, Inc. | One vial method for labeling antibodies with Technetium-99m |
DE68919361T2 (de) | 1988-06-21 | 1995-05-24 | Genentech Inc | Therapeutische zusammensetzungen für die behandlung von myocard-infarkten. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2125854T3 (es) | 1989-08-09 | 1999-03-16 | Rhomed Inc | Radiomarcado directo de anticuerpos y otras proteinas con tecnetio o renio. |
US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
EP0779362B2 (en) | 1989-12-22 | 2012-06-13 | Laboratoires Serono SA | DNA constructs for endogenous gene activation and expression modification |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
JP3149960B2 (ja) | 1991-01-24 | 2001-03-26 | 財団法人化学及血清療法研究所 | ヒト組織因子を定量する方法 |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
US6063630A (en) | 1991-11-05 | 2000-05-16 | Transkaryotic Therapies, Inc. | Targeted introduction of DNA into primary or secondary cells and their use for gene therapy |
US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
JPH05244988A (ja) | 1992-03-04 | 1993-09-24 | Green Cross Corp:The | 抗組織因子モノクローナル抗体、及びこれによる免疫抑制剤 |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994005328A1 (en) | 1992-08-28 | 1994-03-17 | The Scripps Research Institute | Inhibition of tumor metastasis via neutralization of tissue factor function |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
ES2146648T3 (es) | 1993-03-09 | 2000-08-16 | Genzyme Corp | Procedimiento de aislamiento de proteinas de la leche. |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
US5879687A (en) | 1994-04-22 | 1999-03-09 | Corixa Corporation | Methods for enhancement of protective immune responses |
HU220347B (hu) | 1994-07-11 | 2001-12-28 | Board Of Regents The University Of Texas System | Készítmény az érrendszer specifikus koagulálásához |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
PT833911E (pt) | 1995-06-07 | 2004-09-30 | Ortho Mcneil Pharm Inc | Anticorpos anti-factor tecidular enxertados com cdr e metodos para a sua utilizacao |
KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
JPH09302000A (ja) | 1996-05-16 | 1997-11-25 | Chemo Sero Therapeut Res Inst | 抗組織因子モノクローナル抗体及び当該モノクローナル抗体を用いた組織因子凝固活性の測定法 |
US6593291B1 (en) | 1997-02-06 | 2003-07-15 | Entremed, Inc. | Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20040229282A1 (en) | 1997-03-10 | 2004-11-18 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US6719977B1 (en) | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
WO1999050392A1 (en) | 1998-03-31 | 1999-10-07 | Geron Corporation | Methods and compositions for eliciting an immune response to a telomerase antigen |
SK14812000A3 (sk) * | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
DK1108035T3 (da) | 1998-09-04 | 2007-09-24 | Sanofi Pasteur Ltd | Behandling af cervixcancer |
US6387888B1 (en) | 1998-09-30 | 2002-05-14 | American Foundation For Biological Research, Inc. | Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen |
IL144084A0 (en) | 1999-02-03 | 2002-05-23 | Biosante Pharmaceuticals Inc | Therapeutic calcium phosphate particles and methods of manufacture and use |
US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
MXPA02000962A (es) | 1999-07-29 | 2002-07-02 | Medarex Inc | Anticuerpos monoclonales humanos para her2/neu. |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
JP2001213804A (ja) | 2000-01-31 | 2001-08-07 | Chugai Pharmaceut Co Ltd | 抗組織因子抗体の複合体 |
AU2001250814B2 (en) | 2000-03-16 | 2007-02-15 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
WO2002042468A2 (en) | 2000-11-27 | 2002-05-30 | Geron Corporation | Glycosyltransferase vectors for treating cancer |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
WO2002078738A1 (fr) | 2001-03-26 | 2002-10-10 | Koji Suzuki | Agents ameliorant la rheologie sanguine |
US7247304B2 (en) | 2001-08-23 | 2007-07-24 | Genmab A/S | Methods of treating using anti-IL-15 antibodies |
JP4359503B2 (ja) | 2001-08-23 | 2009-11-04 | ゲンマブ エー/エス | インターロイキン15(il−15)に特異的なヒト抗体 |
WO2003020111A2 (en) | 2001-08-30 | 2003-03-13 | Mount Sinai School Of Medicine Of New York University | Alternatively spliced circulating tissue factor |
MXPA04003051A (es) * | 2001-10-02 | 2004-07-05 | Novo Nordisk As | Anticuerpos de factor tisular humano. |
US20050169927A1 (en) * | 2001-10-02 | 2005-08-04 | Novo Nordisk A/S | Human tissue factor antibodies |
TWI338009B (en) | 2001-10-29 | 2011-03-01 | Genentech Inc | Antibodies for inhibiting blood coagulation and methods of use thereof |
WO2003037361A2 (en) | 2001-11-02 | 2003-05-08 | Novo Nordisk Health Care Ag | Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis |
KR20050004785A (ko) | 2002-02-22 | 2005-01-12 | 프롭휘 메드 아베 | 조직 인자의 억제제 또는 길항제의 용도 |
UA85996C2 (ru) | 2002-05-01 | 2009-03-25 | Шеринг Акциенгезельшафт | Слитый антикоагулянтный белок тромбомодулина, который обеспечивает направленное перенесение к тканевому фактору |
AU2003242506A1 (en) | 2002-07-12 | 2004-02-02 | Novo Nordisk A/S | Tf antagonist |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
WO2004039842A2 (en) * | 2002-10-31 | 2004-05-13 | Novo Nordisk A/S | Humanized tissue factor antibodies |
WO2004041296A2 (en) | 2002-11-06 | 2004-05-21 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
AU2003275947A1 (en) | 2002-11-06 | 2004-06-07 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and a blood glucose regulator |
AU2003295471B2 (en) | 2002-11-15 | 2011-08-25 | Genmab A/S | Human monoclonal antibodies against CD25 |
EP1590364B1 (en) | 2002-12-16 | 2011-10-05 | Genmab A/S | Human monoclonal antibodies against interleukin 8 (il-8) |
EP1587549A2 (en) | 2003-01-22 | 2005-10-26 | Novo Nordisk A/S | Radiolabelled tissue factor binding agent and the use thereof |
US20060034846A1 (en) | 2003-04-14 | 2006-02-16 | Mirella Ezban | Use of TF antagonists |
US7425328B2 (en) | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
WO2005000896A2 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Polypeptides that bind an anti-tissue factor antibody and uses thereof |
KR20060035608A (ko) | 2003-05-30 | 2006-04-26 | 센토코 인코포레이티드 | 항 조직 인자 항체로 종양 성장을 저해하는 방법 |
US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
KR100912381B1 (ko) | 2003-06-19 | 2009-08-19 | 타녹스 인코퍼레이티드 | 응고 관련 질병을 치료하기 위한 조성물 및 방법 |
WO2005025623A2 (en) | 2003-07-28 | 2005-03-24 | Emory University | Ef-24-factor vii conjugates |
JP2007504167A (ja) | 2003-08-29 | 2007-03-01 | セントカー・インコーポレーテツド | 抗組織因子抗体を用いる移植片の生存を向上する方法 |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
PL1691837T3 (pl) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | IP-10 przeciwciała i ich zastosowanie |
JP2007523099A (ja) | 2004-02-20 | 2007-08-16 | ノボ ノルディスク アクティーゼルスカブ | 組み合わせ療法 |
US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
AU2006338560A1 (en) | 2005-10-21 | 2007-08-30 | Genentech, Inc. | Treatment for antiphospholipid-syndrome-related pregnancy complications |
JP5191392B2 (ja) | 2005-11-07 | 2013-05-08 | ザ スクリプス リサーチ インスティチュート | 組織因子シグナル伝達の特異性を調節するための組成物及び方法 |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
WO2007076091A2 (en) | 2005-12-22 | 2007-07-05 | Genentech, Inc. | Treatment of viral infections using a tissue factor inhibitor |
EP2148929A4 (en) | 2007-04-30 | 2011-03-23 | Centocor Ortho Biotech Inc | TISSUE ANTI-FACTOR ANTIBODIES AND COMPOSITIONS WITH INCREASED EFFECTOR FUNCTION |
UA109633C2 (uk) * | 2008-12-09 | 2015-09-25 | Антитіло людини проти тканинного фактора | |
JP6055404B2 (ja) | 2010-06-15 | 2016-12-27 | ゲンマブ エー/エス | 組織因子に対するヒト抗体薬物結合体 |
-
2009
- 2009-09-12 UA UAA201108545A patent/UA109633C2/ru unknown
- 2009-12-09 KR KR1020117015836A patent/KR101736447B1/ko active IP Right Grant
- 2009-12-09 SG SG10201500140VA patent/SG10201500140VA/en unknown
- 2009-12-09 NZ NZ786274A patent/NZ786274A/en unknown
- 2009-12-09 PT PT98014269T patent/PT2376537T/pt unknown
- 2009-12-09 KR KR1020177012653A patent/KR101998492B1/ko active IP Right Grant
- 2009-12-09 CA CA2746101A patent/CA2746101C/en active Active
- 2009-12-09 PL PL09801426T patent/PL2376537T3/pl unknown
- 2009-12-09 CN CN200980156348.7A patent/CN102317319B/zh active Active
- 2009-12-09 BR BRPI0922350A patent/BRPI0922350B8/pt active IP Right Grant
- 2009-12-09 MX MX2011005669A patent/MX338754B/es active IP Right Grant
- 2009-12-09 EA EA201100923A patent/EA201100923A1/ru unknown
- 2009-12-09 EP EP16185529.1A patent/EP3159358B1/en active Active
- 2009-12-09 EP EP23202086.7A patent/EP4279140A3/en active Pending
- 2009-12-09 SI SI200931566A patent/SI2376537T1/sl unknown
- 2009-12-09 CA CA3017575A patent/CA3017575A1/en active Pending
- 2009-12-09 JP JP2011540083A patent/JP5860285B2/ja active Active
- 2009-12-09 CN CN201610367892.8A patent/CN106632678B/zh active Active
- 2009-12-09 US US13/133,811 patent/US9150658B2/en active Active
- 2009-12-09 ES ES09801426.9T patent/ES2604635T3/es active Active
- 2009-12-09 AU AU2009324412A patent/AU2009324412B2/en active Active
- 2009-12-09 DK DK09801426.9T patent/DK2376537T3/en active
- 2009-12-09 EP EP09801426.9A patent/EP2376537B1/en active Active
- 2009-12-09 WO PCT/EP2009/066755 patent/WO2010066803A2/en active Application Filing
-
2011
- 2011-05-12 IL IL212856A patent/IL212856A/en active IP Right Grant
- 2011-05-20 ZA ZA2011/03723A patent/ZA201103723B/en unknown
- 2011-05-27 MX MX2016005494A patent/MX355181B/es unknown
-
2015
- 2015-08-28 US US14/839,514 patent/US9714297B2/en active Active
- 2015-12-18 JP JP2015246927A patent/JP6236056B2/ja active Active
-
2017
- 2017-06-19 US US15/626,866 patent/US20180044431A1/en not_active Abandoned
- 2017-10-27 JP JP2017207768A patent/JP6592491B2/ja active Active
-
2018
- 2018-08-16 US US15/998,816 patent/US20190169311A1/en not_active Abandoned
-
2019
- 2019-09-20 JP JP2019171368A patent/JP7069095B2/ja active Active
-
2020
- 2020-05-21 US US16/880,241 patent/US20210171657A1/en not_active Abandoned
-
2022
- 2022-01-28 JP JP2022011455A patent/JP2022078018A/ja active Pending
- 2022-12-06 US US18/062,473 patent/US20230416403A1/en active Pending
-
2023
- 2023-10-31 JP JP2023186212A patent/JP2024001285A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355181B (es) | Anticuerpos humanos contra el factor tisular. | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
MX340295B (es) | Anticuerpos monoclonales anti-c-met. | |
MX2007011064A (es) | Anticuerpos contra cd38 para tratamiento de mieloma multiple. | |
EP3539988A3 (en) | Monoclonal antibodies against her2 | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
SG184310A1 (en) | Antibodies that bind human cd27 and uses thereof | |
MX2010005022A (es) | Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas. | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
UA107490C2 (uk) | TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК | |
RS20140203A1 (en) | IMMUNOVELING PROTEINS AGAINST TNF | |
WO2011147982A3 (en) | Monoclonal antibodies against her2 epitope | |
MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
MX347893B (es) | Conjugados de farmaco y anticuerpo humano contra factor de tejido. | |
MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
EP2582722A4 (en) | ANTIBODIES AGAINST GD2 | |
MX2020012426A (es) | Anticuerpos anti-cd38. | |
NZ593314A (en) | Dual variable domain immunoglobulins and uses thereof | |
MX2013007067A (es) | Anticuerpos anti-il-18 y sus usos. | |
WO2011112566A3 (en) | Basigin binding proteins | |
EA202190387A1 (ru) | Антитело к cd38 человека и его применение | |
UA109423C2 (uk) | Композиція та спосіб для діагностики і лікування пухлини | |
SG10201909377XA (en) | Antibodies that bind human cd27 and uses thereof |